Vericel Receives FDA Fast Track Designation for Ixmyelocel-T, an Investigational Product for the Treatment of Patients with Advanced Heart Failure Due to Ischemic Dilated Cardiomyopathy
Vericel Corporation (VCEL)
Last vericel corporation earnings: 2/25 08:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.vcel.com/investor-relations
Company Research
Source: GlobeNewswire
CAMBRIDGE, Mass., Feb. 21, 2017 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of autologous expanded cell therapies for the treatment of patients with serious diseases and conditions, today announced that the U.S. Food and Drug Administration (FDA) has designated the investigation of ixmyelocel-T for reduction in the risk of death and cardiovascular hospitalization in patients with chronic advanced heart failure due to ischemic dilated cardiomyopathy as a Fast Track Development Program. “Receiving Fast Track designation highlights both the unmet medical need for improved therapies to treat advanced heart failure due to dilated cardiomyopathy and the significance of the results from the ixmyelocel-T Phase 2b ixCELL-DCM clinical study” said Nick Colangelo, president and CEO of Vericel. "We believe that achieving important regulatory milestones such as Fast Track designation enhances the value of ixmyelocel-T and our efforts to partner the further developm
Show less
Read more
Impact Snapshot
Event Time:
VCEL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VCEL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VCEL alerts
High impacting Vericel Corporation news events
Weekly update
A roundup of the hottest topics
VCEL
News
- Vericel Corporation (NASDAQ:VCEL) On The Verge Of Breaking Even [Yahoo! Finance]Yahoo! Finance
- Global Cell and Gene Therapy Markets Report 2024-2028 Featuring Main Players - Mallinckrodt, Vericel, Gilead Sciences, Pharmicell, and Bristol-Myers Squibb [Yahoo! Finance]Yahoo! Finance
- Vericel Co. (NASDAQ: VCEL) had its "buy" rating re-affirmed by analysts at Truist Financial Co.. They now have a $54.00 price target on the stock.MarketBeat
- Treatment Options to Help Overcome Knee Pain for Sports Enthusiasts [Yahoo! Finance]Yahoo! Finance
- US$52.07 - That's What Analysts Think Vericel Corporation (NASDAQ:VCEL) Is Worth After These Results [Yahoo! Finance]Yahoo! Finance
VCEL
Earnings
- 2/29/24 - Beat
VCEL
Analyst Actions
- 1/30/24 - TheStreet
VCEL
Sec Filings
- 4/19/24 - Form 4
- 4/18/24 - Form 144
- 4/17/24 - Form 144
- VCEL's page on the SEC website